Source: Financial Supervisory Service Data Analysis, Retrieval and Transfer System (DART) / 2026-04-24
Disclosure Type: Major Business Matters Related to Investment Decisions
💡 3-Second Summary
On April 23, 2026, Celltrion officially received approval from the Ministry of Food and Drug Safety (MFDS) of South Korea for its global Phase 3 clinical trial protocol amendment concerning the Keytruda biosimilar candidate, CT-P51.
📊 1. [Key Disclosure Details & Major Figures Summary]
- Investigational Product & Reference Drug: CT-P51 (Reference Product: Keytruda)
- Indication: Metastatic Non-Squamous Non-Small Cell Lung Cancer
- Clinical Trial Phase: Global Phase 3 Trial
- Trial Application & Approval Details:
- Filing Date: March 30, 2026
- Approval Date: April 23, 2026 (Fact confirmation date: April 24, 2026)
- Approving Authority: South Korea Ministry of Food and Drug Safety (MFDS)
- Protocol Specifications:
- Number of Subjects: 220 patients
- Treatment Duration: 2 years of treatment
- Trial Design: Randomized, double-blind, active-controlled, parallel-group, Phase 3 clinical trial
- Clinical Trial Registration Number: EU CT number 2024-514048-98-00
- Note: The official disclosure text does not state the precise reasons or specific protocol modifications (such as modifications in patient population, clinical endpoints, or dosing regimens) that led to this protocol amendment filing.
📈 2. [Expert Perspective: What This Means for Investors]
- Regulatory Approval of Protocol Amendment: This filing provides objective verification that the protocol amendment for the global Phase 3 trial submitted on March 30, 2026, has been officially cleared by the South Korean regulatory authority. With this administrative milestone completed, Celltrion is authorized to proceed with the trials under the approved amended protocol.
- Omission of Specific Changes and Background: Because the document does not disclose the specific structural changes made to the trial design or the strategic reasons behind the amendment, market participants should avoid assuming any changes in development speed. The operational impacts should be evaluated only as subsequent official reports or verified details are disclosed.
- Understanding Clinical Development Risks: According to the cautionary warning, the statistical probability of an investigational drug obtaining final marketing authorization is approximately 10%. Investors should remain aware that unexpected efficacy or safety outcomes during the Phase 3 process may lead to changes in or abandonment of the commercialization plan.
📝 Editor’s Comment (by K-STOCK Editor)
This regulatory disclosure strictly reports the quantitative administrative update that the protocol amendment for Celltrion’s Keytruda biosimilar (CT-P51) has been approved by the MFDS. Since the document does not specify whether trials were paused or how the timelines might adjust, readers should refrain from assuming any operational halts or resumptions. The objective focus for investors is simply verifying that the 2-year trial proceeds as scheduled under the approved amendment and waiting for official clinical trial data.
📢 Disclaimer & Sources
Source: This content has been newly structured and written based on official data submitted to the Financial Supervisory Service’s Data Analysis, Retrieval and Transfer System (DART).
Investment Risk Warning: This content is provided for informational and linguistic reference purposes only. Under no circumstances does it constitute financial advice or a recommendation to buy or sell specific stocks. All investment decisions and financial responsibilities rest entirely with the investor.
Contact: For compliance inquiries or copyright-related requests, please contact ksb220805@gmail.com.
🔥 Bulls vs Bears, drop your analysis in the comments!
